Keryx Biopharmaceuticals Inc. (KERX)

4.89
0.04 0.82
NASDAQ : Health Technology
Prev Close 4.85
Open 4.84
Day Low/High 4.77 / 4.93
52 Wk Low/High 4.01 / 8.38
Volume 1.04M
Avg Volume 1.53M
Exchange NASDAQ
Shares Outstanding 119.22M
Market Cap 536.50M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

KERX January 2020 Options Begin Trading

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading today, for the January 2020 expiration.

Interesting KERX Put And Call Options For June 2018

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading this week, for the June 2018 expiration.

Keryx Biopharmaceuticals Becomes Oversold (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

KERX Crosses Above Average Analyst Target

KERX Crosses Above Average Analyst Target

In recent trading, shares of Keryx Biopharmaceuticals Inc. have crossed above the average analyst 12-month target price of $7.67, changing hands for $7.95/share.

First Week of KERX November 17th Options Trading

Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the November 17th expiration.

Keryx Biopharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Keryx Biopharmaceuticals Inc. have crossed above the average analyst 12-month target price of $7.67, changing hands for $7.80/share.

First Week of October 20th Options Trading For Keryx Biopharmaceuticals (KERX)

Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the October 20th expiration.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

KERX Crosses Above Average Analyst Target

In recent trading, shares of Keryx Biopharmaceuticals Inc. have crossed above the average analyst 12-month target price of $6.83, changing hands for $6.84/share.

Interesting KERX Put And Call Options For December 15th

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.

TheStreet Quant Rating: D- (Sell)